Overview
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
Status:
Terminated
Terminated
Trial end date:
2008-05-01
2008-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Bevacizumab
Criteria
Inclusion Criteria:- Adult patients, 19-75 years of age
- Multiple myeloma.
- Progressive disease after at least 2 lines of prior therapy.
Exclusion Criteria:
- Non-secretory myeloma.
- History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer
in situ of the cervix within the last 5 years.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study treatment start.
- Clinically significant cardiac disease.